Stock of Neurocrine Biosciences gained almost 50% for the last week on Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. This security should rest for a some time; short sell – period. Neurocrine Biosciences Announces That VMAT2 Program Will Move Into Phase II Clinical Trials PR Newswire “Press Releases US […]